| |
Cerus Corporation is a biopharmaceutical company focused on the development and commercialization of the INTERCEPT Blood System. The INTERCEPT system is designed to inactivate blood-borne pathogens in donated blood components intended for transfusion. The company currently markets the INTERCEPT system for both platelets and plasma in Europe and, through distributors and licensees, in countries around the world that recognize the CE mark. The company is also in Phase I clinical trials for development of the INTERCEPT system for red blood cells in the United States. |
|
|
View Cerus hosted ISBT Symposium: A Single Pathogen Inactivation System for Two Blood Components: INTERCEPT Blood System for Platelets and Plasma
June 26, 2007 Madrid, Spain |
